DOCSLIB.ORG

Hsa-Mir-125B-2 Is Highly Expressed in Childhood ETV6&Sol;RUNX1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hsa-Mir-125B-2 Is Highly Expressed in Childhood ETV6&Sol;RUNX1 Leukemia (2010) 24, 89–96 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 N Gefen1,2,8, V Binder1,3,8, M Zaliova4, Y Linka3, M Morrow6, A Novosel3, L Edry5, L Hertzberg1,2,7, N Shomron5, O Williams6, J Trka4, A Borkhardt3 and S Izraeli1,2 1Section of Functional Genomics and Leukemia Research, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel-Hashomer, Israel; 2Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Department of Pediatric Hematology, Oncology and Immunology, Heinrich Heine University, Duesseldorf, Germany; 4Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Childhood Leukemia Investigation Prague, Prague, Czech Republic; 5Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 6Institute of Child Health, University College London, London, UK and 7Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel MicroRNAs (miRNAs) regulate the expression of multiple characterized by an intrachromosomal amplification of a small proteins in a dose-dependent manner. We hypothesized that region within the long arm of chr 21 (iAMP21) around the increased expression of miRNAs encoded on chromosome 21 4 (chr 21) contribute to the leukemogenic function of trisomy 21. RUNX1 locus. In contrast to ETV6/RUNX1 and HHD ALL, it is The levels of chr 21 miRNAs were quantified by qRT–PCR in associated with poor prognosis. The most common structural four types of childhood acute lymphoblastic leukemia (ALL) chromosomal aberration in childhood ALL occurring in characterized by either numerical (trisomy or tetrasomy) or approximately 25% of pediatric B-cell precursor ALL fuses the structural abnormalities of chr 21. Suprisingly, high expression RUNX1 (AML1) gene on chr 21 with the ETV6 (TEL) gene on chr of the hsa-mir-125b-2 cluster, consisting of three miRNAs, 12.5,6 Although ETV6/RUNX1 causes a prenatal preleukemic was identified in leukemias with the structural ETV6/RUNX1 clonal expansion, additional genetic events are required for abnormality and not in ALLs with trisomy 21. Manipulation of 7,8 ETV6/RUNX1 expression and chromatin immunoprecipitation evolution of leukemia. studies showed that the high expression of the miRNA cluster MicroRNAs (miRNAs) are 20–25 nucleotide long non-coding is an event independent of the ETV6/RUNX1 fusion protein. RNAs that have a vital function in the regulation of protein Overexpression of hsa-mir-125b-2 conferred a survival advan- expression.9 Currently, there are six validated mature miRNAs tage to Ba/F3 cells after IL-3 withdrawal or a broad spectrum of encoded on human chr 21 (http://microrna.sanger.ac.uk apoptotic stimuli through inhibition of caspase 3 activation. Conversely, knockdown of the endogenous miR-125b in the Figure 1a). Hsa-mir-99a, hsa-let-7c and hsa-mir-125b-2 are ETV6/RUNX1 leukemia cell line REH increased apoptosis after clustered together in the same intron of the C21ORF34 gene Doxorubicin and Staurosporine treatments. P53 protein levels on 21q.21.1 (NC_000021.7) (hsa-mir-125b-2 cluster). Hsa-mir- were not altered by miR-125b. Together, these results suggest 125b-1, the homolog of Caenorhabditis elegans lin-4, has been that the expression of hsa-mir-125b-2 in ETV6/RUNX1 ALL shown to be expressed in solid tumors and associated with provides survival advantage to growth inhibitory signals in a enhanced cell proliferation and survival.10–12 An insertion of hsa- p53-independent manner. Leukemia (2010) 24, 89–96; doi:10.1038/leu.2009.208; mir-125b-1 into the IGH locus was described in a patient with B- published online 5 November 2009 cell precursor ALL suggesting its involvement in the leukemic 13 Keywords: acute lymphoblastic leukemia (ALL); ETV6/RUNX1; process. It has been shown to be expressed in myeloid TEL/AML1; microRNA malignancies and to block myeloid differentiation.14 Recently, it was also reported to protect from apoptosis through negative regulation of p53 in zebrafish, human neuroblastoma cells and Introduction lung fibroblasts, but not in mouse cells.15 Hsa-mir-155 has been linked to B-cell development. Others and we have shown its Aberrations in chromosome 21 (chr 21) are commonly found in increased expression in lymphomas.16–19 Strikingly, transgenic childhood acute lymphoblastic leukemia (ALL). The high- expression of miR-155 induced pre-B-cell leukemias and lymphomas 1,2 hyperdiploid ALL (HHD ALL), the most common type of in mice,20 thus miR-155 seems to be a potent oncogene. childhood ALL with numerical chromosomal aberrations, is The mechanisms of miRNA function suggest that their activity characterized by 3–4 copies of chr 21 and a variable presence of should be correlated with their dosage and that each miRNA other specific chromosomal trisomies. The markedly increased may regulate multiple targets.21 Thus, we hypothesized that 3 incidence of ALL in children with Down’s syndrome (DS) miRNAs contribute to the oncogenic effects of chromosomal strongly suggests that trisomy 21 is leukemogenic, but the chr 21 trisomies, a situation in which a small change ( Â 1.5) in genes involved in these leukemias are presently unknown. genomic dosage results in profound effects. This hypothesis is A newly discovered rare subtype of childhood ALL is strengthened by our recent observations showing a general increase in expression of multiple genes from the trisomic Correspondence: Professor S Izraeli, Section of Functional Genomics chromosomes.22 Thus, we expected that miRNAs from chr 21 and Leukemia Research, Department of Pediatric Hemato-Oncology, would be overexpressed in HHD and DS ALL (3–4 copies of chr Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel. 21) relative to ETV6/RUNX1 and iAMP21 leukemias. E-mail: [email protected] 8These two authors contributed equally to this work. Here, we report the surprising observations that unlike most of Received 2 February 2009; revised 17 August 2009; accepted 4 the genes encoded on chr 21, the expression of the hsa-mir- September 2009; published online 5 November 2009 125b-2 cluster does not correlate with gene copy number, but MicroRNA in ETV6/RUNX1 ALL N Gefen et al 90 miR-155 iAMP21- ETV6/RUNX1 ALL ALL 4.0 HHD ALL 3.5 DS ALL 3.0 iAMP21 ALL 2.5 p13 p11.2 q11.2 q21.2 q21.3 q22.11 q22.12 q22.13 q22.2 q22.3 q21.1 2.0 * * 1.5 1.0 * 0.5 0.0 miR-802 let-7c miR-99a miR-125b miR-155 “miR-125b cluster“: Hsa-miR-let-7c Hsa-miR-99a Hsa-miR-125b 3.5 ETV6/RUNX1 initial 3 ETV6/RUNX1 remission * 2.5 2 * * 1.5 1 * 0.5 0 let-7c miR-99a miR-125b miR-155 Figure 1 Expression of miRNAs encoded on chr 21 in different leukemia samples. (a) Schematic representation of the location of miRNAs encoded on chr 21. The level of the mature hsa-miR-802 could not be measured because of the lack of an appropriate qRT–PCR-based assay. (b, c) MiRNA expression was determined by qRT–PCR using the TaqMan MicroRNA Assays from Applied Biosystems. The numbers on the y axis represent relative expression levels of mature miRNA normalized to an internal control (RNU43). Standard errors are indicated. Asterisk marks significance. (b) Expression of the chr 21 miRNAs in diagnostic bone marrow samples of different ALL subtypes: ETV6/RUNX1 (24 patients), DS (10 patients), high hyperdiploid (10 patients), iAMP21 (7 patients) Po0.05 (ANOVA). (c) Comparison of miRNA expression between diagnosis and remission samples of ETV6/RUNX1 leukemias Po0.005 (T-test). rather is highly expressed in ETV6/RUNX1 ALL. Additional ALL (n ¼ 7). Surprisingly, extra copies of chr 21 did not research suggests that the expression of the hsa-miR-125b-2 contribute to the expression level of these miRNAs (Figure 1b). cluster is an independent event in ETV6/RUNX1 ALL, conferring Although hsa-mir-155 is similarly expressed between the survival advantage under growth inhibitory and apoptotic different ALLs, the other miRNAs hsa-mir-99a, hsa-let-7c and conditions in a p53-independent manner. hsa-mir-125b-2 are up-regulated in the ETV6/RUNX1 ALL, the subtype of leukemia with a structural aberration of chr 21. The expression was derived from the leukemic blasts, as it was Materials and methods not observed in remission samples (Figure 1c). To ensure that the observed results were not because of the normalization to a Patients single internal control (RNU 43), we have extended the miRNA RNA was derived from diagnostic or remission bone marrow profiling using TaqMan Low Density miRNA arrays (TLDA, ABI) samples of childhood ALL patients obtained with informed normalizing to two additional internal controls (RNU6 and consent. Diagnostic bone marrow samples contained at least RNU48). As can be seen in Supplementary Figure 1, the TLDA 80% lymphoblasts. The samples were anonymized before results are similar to the results obtained with the singleplex shipping except for the information on the genetic subgroup. miRNA expression profiling. The study was approved by the IRB of the Israeli Health Ministry and Sheba Medical Center. The rest of the material and methods are detailed in a Hsa-mir-125b-2 cluster is not a target of the ETV6/ supplementary file. RUNX1 fusion protein To test whether mir-125b-2 is a target of ETV6/RUNX1, we performed overexpression experiments in two mouse hemato- Results poietic progenitor cell systems: Ba/F3 cells and primary mouse embryonic fetal liver progenitors.
Load more

Recommended publications
  • Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development
    International Journal of Molecular Sciences Review Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development Charles Ducker * and Peter E. Shaw * Queen’s Medical Centre, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK * Correspondence: [email protected] (C.D.); [email protected] (P.E.S.) Abstract: Genome expansion, whole genome and gene duplication events during metazoan evolution produced an extensive family of ETS genes whose members express transcription factors with a conserved winged helix-turn-helix DNA-binding domain. Unravelling their biological roles has proved challenging with functional redundancy manifest in overlapping expression patterns, a common consensus DNA-binding motif and responsiveness to mitogen-activated protein kinase signalling. Key determinants of the cellular repertoire of ETS proteins are their stability and turnover, controlled largely by the actions of selective E3 ubiquitin ligases and deubiquitinases. Here we discuss the known relationships between ETS proteins and enzymes that determine their ubiquitin status, their integration with other developmental signal transduction pathways and how suppression of ETS protein ubiquitination contributes to the malignant cell phenotype in multiple cancers. Keywords: E3 ligase complex; deubiquitinase; gene fusions; mitogens; phosphorylation; DNA damage 1. Introduction Citation: Ducker, C.; Shaw, P.E. Cell growth, proliferation and differentiation are complex, concerted processes that Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer rely on careful regulation of gene expression. Control over gene expression is maintained and Development. Int. J. Mol. Sci. through signalling pathways that respond to external cellular stimuli, such as growth 2021, 22, 5119. https://doi.org/ factors, cytokines and chemokines, that invoke expression profiles commensurate with 10.3390/ijms22105119 diverse cellular outcomes.
    [Show full text]
  • HDAC3: Taking the SMRT-N-Correct Road to Repression
    Oncogene (2007) 26, 5439–5449 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW HDAC3: taking the SMRT-N-CoRrect road to repression P Karagianni and J Wong1 Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA Known histone deacetylases (HDACs) are divided into repression when targeted to promoters, as well as different classes, and HDAC3 belongs to Class I. Through physical association with the DNA-binding factor forming multiprotein complexes with the corepressors YY1 (Yang et al., 1997; Dangond et al., 1998; Emiliani SMRT and N-CoR, HDAC3 regulates the transcription et al., 1998). Together, these findings suggested that this of a plethora of genes. A growing list of nonhistone ubiquitously expressed protein could be involved in the substrates extends the role of HDAC3 beyond transcrip- regulation of mammalian gene expression. On the other tional repression. Here, we review data on the composi- hand, HDAC3 contains an intriguingly variable C tion, regulation and mechanism of action of the SMRT/ terminus, with no apparent similarity with other N-CoR-HDAC3 complexes and provide several examples HDACs. This observation led to the hypothesis that of nontranscriptional functions, to illustrate the wide HDAC3 may have some unique properties and may variety of physiological processes affected by this deacety- not be completely redundant with the other HDACs lase. Furthermore, we discuss the implication of HDAC3 (Yang et al., 1997). This is also suggested by the in cancer, focusing on leukemia. We conclude with some differential localization of HDAC3, which, unlike the thoughts about the potential therapeutic efficacies of predominantly nuclear HDACs 1 and 2, can be found in HDAC3 activity modulation.
    [Show full text]
  • The Complex Genetic Landscape of Familial MDS and AML Reveals Pathogenic Germline Variants
    ARTICLE https://doi.org/10.1038/s41467-020-14829-5 OPEN The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants Ana Rio-Machin et al.# The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we report a cohort of 86 acute myeloid leukemia (AML) and 1234567890():,; myelodysplastic syndrome (MDS) families with 49 harboring germline variants in 16 pre- viously defined loci (57%). Whole exome sequencing in a further 37 uncharacterized families (43%) allowed us to rationalize 65 new candidate loci, including genes mutated in rare hematological syndromes (ADA, GP6, IL17RA, PRF1 and SEC23B), reported in prior MDS/AML or inherited bone marrow failure series (DNAH9, NAPRT1 and SH2B3) or variants at novel loci (DHX34) that appear specific to inherited forms of myeloid malignancies. Altogether, our series of MDS/AML families offer novel insights into the etiology of myeloid malignancies and provide a framework to prioritize variants for inclusion into routine diagnostics and patient management. #A full list of authors and their affiliations appears at the end of the paper. NATURE COMMUNICATIONS | (2020) 11:1044 | https://doi.org/10.1038/s41467-020-14829-5 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14829-5 nherited forms of myeloid malignancies are thought to be rare, Results Ialthough the precise
    [Show full text]
  • An Integrative Approach Reveals Genetic Complexity and Epigenetic
    Human Pathology (2019) 91,1–10 www.elsevier.com/locate/humpath Original contribution An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience☆ Nina Rahimi MD a,YanmingZhangMDb, Alain Mina MD c, Jessica K. Altman MD c, Madina Sukhanova PhD a, Olga Frankfurt MD c, Lawrence Jennings MD, PhD a, Xinyan Lu MD a,AmirBehdadMDa, Qing Chen MD, PhD a, Yi-Hua Chen MD a, Juehua Gao MD, PhD a,⁎ aDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA bDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA cDepartment of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA Received 10 March 2019; revised 8 May 2019; accepted 8 May 2019 Keywords: Summary Acute promyelocytic leukemia (APL) is a distinct type of acute myeloid leukemia that is Acute promyelocytic defined by the presence of the translocations that mostly involve the RARA gene. The most frequent leukemia; translocation is the t(15;17), which fuses the RARA gene with the PML gene. Previous studies have Next-generation shown that other cooperative mutations are required for the development of APL after the initiating sequencing; event of the t(15;17). In this study, we combined cytogenetics with next-generation sequencing and Somatic mutations; single-nucleotide polymorphism array to study the genetic complexity in 20 APL cases diagnosed in our in- SNP array; stitution. All but 3 cases had additional genetic aberrations. Our study demonstrated that somatic mutations Copy neutral loss of are frequent events in APL.
    [Show full text]
  • Immunohistochemical Expression of Wilms' Tumor 1 Protein In
    applied sciences Review Immunohistochemical Expression of Wilms’ Tumor 1 Protein in Human Tissues: From Ontogenesis to Neoplastic Tissues Lucia Salvatorelli 1,*, Giovanna Calabrese 2 , Rosalba Parenti 2 , Giada Maria Vecchio 1, Lidia Puzzo 1, Rosario Caltabiano 1 , Giuseppe Musumeci 3 and Gaetano Magro 1 1 Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, Anatomic Pathology Section, School of Medicine, University of Catania, 95123 Catania, Italy; [email protected] (G.M.V.); [email protected] (L.P.); [email protected] (R.C.); [email protected] (G.M.) 2 Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy; [email protected] (G.C.); [email protected] (R.P.) 3 Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, 95123 Catania, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-095-3702138; Fax: +39-095-3782023 Received: 4 October 2019; Accepted: 10 December 2019; Published: 19 December 2019 Abstract: The human Wilms’ tumor gene (WT1) was originally isolated in a Wilms’ tumor of the kidney as a tumor suppressor gene. Numerous isoforms of WT1, by combination of alternative translational start sites, alternative RNA splicing and RNA editing, have been well documented. During human ontogenesis, according to the antibodies used, anti-C or N-terminus WT1 protein, nuclear expression can be frequently obtained in numerous tissues, including metanephric and mesonephric glomeruli, and mesothelial and sub-mesothelial cells, while cytoplasmic staining is usually found in developing smooth and skeletal cells, myocardium, glial cells, neuroblasts, adrenal cortical cells and the endothelial cells of blood vessels.
    [Show full text]
  • Germline Mutations in Etv6 Result in Autosomal Dominant
    GERMLINE MUTATIONS IN ETV6 RESULT IN AUTOSOMAL DOMINANT THROMBOCYTOPENIA By LEILA J. NOETZLI B.S., University of California San Diego, 2007 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Human Medical Genetics and Genomics Program 2017 This thesis for the Doctor of Philosophy degree by Leila J. Noetzli has been approved for the Human Medical Genetics and Genomics Program by Robert Sclafani, Chair Jorge Di Paola, Advisor Jay Hesselberth Richard Spritz Rytis Prekeris Date: May 19, 2017 ii Noetzli, Leila J. (Ph.D., Human Medical Genetics and Genomics) Germline mutations in ETV6 result in autosomal dominant thrombocytopenia Thesis directed by Associate Professor Jorge Di Paola ABSTRACT Whole exome sequencing on a family with autosomal dominant thrombocytopenia and two occurrences of acute lymphoblastic leukemia (ALL) of unknown cause identified a heterozygous single nucleotide change in the gene ETV6, encoding a p.Pro214Leu amino acid substitution. We screened families with the same phenotype and found mutations in ETV6 in two additional families: one with the identical p.Pro214Leu mutation and one with a p.Arg418Gly substitution. ETV6 is a transcriptional repressor that functions through self-oligomerization and is essential for hematopoietic stem cell proliferation and platelet production in mice. Our report was among the first to describe pathogenic germline mutations in ETV6. Functional characterization of the corresponding ETV6 protein mutations showed aberrant cytoplasmic localization, impaired transcriptional repression, and delayed megakaryocyte maturation. Furthermore, we found that mutant ETV6 protein oligomerizes with WT ETV6 and sequesters it from the nucleus suggesting a dominant negative mechanism.
    [Show full text]
  • (NGS) for Primary Endocrine Resistance in Breast Cancer Patients
    Int J Clin Exp Pathol 2018;11(11):5450-5458 www.ijcep.com /ISSN:1936-2625/IJCEP0084102 Original Article Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients Ruoyang Li1*, Tiantian Tang1*, Tianli Hui1, Zhenchuan Song1, Fugen Li2, Jingyu Li2, Jiajia Xu2 1Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 2Institute of Precision Medicine, 3D Medicines Inc., Shanghai, China. *Equal contributors. Received August 15, 2018; Accepted September 22, 2018; Epub November 1, 2018; Published November 15, 2018 Abstract: Multiple mechanisms have been detected to account for the acquired resistance to endocrine therapies in breast cancer. In this study we retrospectively studied the mechanism of primary endocrine resistance in estrogen receptor positive (ER+) breast cancer patients by next-generation sequencing (NGS). Tumor specimens and matched blood samples were obtained from 24 ER+ breast cancer patients. Fifteen of them displayed endocrine resistance, including recurrence and/or metastases within 24 months from the beginning of endocrine therapy, and 9 pa- tients remained sensitive to endocrine therapy for more than 5 years. Genomic DNA of tumor tissue was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks. Genomic DNA of normal tissue was extracted from peripheral blood mononuclear cells (PBMC). Sequencing libraries for each sample were prepared, followed by target capturing for 372 genes that are frequently rearranged in cancers. Massive parallel
    [Show full text]
  • ETV6/GOT1 Fusion in a Case of T(10;12)(Q24;P13)- Sis of Refractory Anemia with Excess Blasts (RAEB)
    Letters to the Editor bone marrow showed 10% blasts establishing the diagno- ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)- sis of refractory anemia with excess blasts (RAEB). Five positive myelodysplastic syndrome months later, she was admitted with a fever. A bone mar- row evaluation confirmed the transformation to an acute myeloid leukemia (AML) M1 according to the FAB classi- The ETV6/GOT1 fusion, resulting from t(10;12) fication. The patient died five days later. (q24;p13), has been recently described in a myelo- At diagnosis, karyotype revealed 46,XX,del(5)(q13q34) dysplastic syndrome. We reported a second case of [11]/46,idem,t(10;12)(q24;p13)[5]/46,XX[6]. The cytoge- t(10;12)-positive myelodysplastic syndrome in netic analysis at transformation displayed:46,XX,der whom fluorescent in situ hybridization confirmed (2)t(2;11)(q34;q14~21),del(5)(q13q34),idic(8)(p12),t(10;12) the non-random translocation but molecular biol- (q24;p13)[22]. ogy analyses revealed a ETV6/GOT1 chimera vary- As this case was very similar to the one previously ing from the first case described. described,6 we tested the hypothesis of a fusion involving ETV6 and GOT1 genes. Hybridization with the Citation: Struski S, Mauvieux L, Gervais C, Hélias C, Liu KL, and Lessard M. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome. Haematologica ETV6/AML1 probe (Abbott), which covers the SAM 2008 Mar; 93(3):467-468. doi: 10.3324/haematol.11988 domain of ETV6, and BAC RP11-441O15 (RZPD, Berlin, Germany) for the GOT1 locus, confirmed fusion signals of ETV6 (ets variant gene 6) is frequently rearranged in ETV6 and GOT1 on both derivative chromosomes 12 and both myeloid and lymphoid hematologic malignancies and 10 (Figure 1A).
    [Show full text]
  • ETS Fusion Genes in Prostate Cancer
    D Gasi Tandefelt et al. ETS fusion genes in prostate 21:3 R143–R152 Review cancer ETS fusion genes in prostate cancer Correspondence 1 2 1 1 Delila Gasi Tandefelt , Joost Boormans , Karin Hermans and Jan Trapman should be addressed to D Gasi Tandefelt Departments of 1Pathology and 2Urology, Erasmus University Medical Centre, PO Box 2040, 2000 CA Rotterdam, Email The Netherlands [email protected] Abstract Prostate cancer is very common in elderly men in developed countries. Unravelling the Key Words molecular and biological processes that contribute to tumor development and progressive " prostate cancer growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and " gene fusion TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene " androgen regulation that encodes a member of the family of ETS transcription factors. At lower frequency, other " ETS gene members of this gene family are also rearranged and overexpressed in prostate cancer. " prostate specific TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate. " translocation Most of the less frequent ETS fusion partners are also androgen-regulated and prostate- specific. During the last few years, novel concepts of the process of gene fusion have emerged, and initial experimental results explaining the function of the ETS genes ERG and ETV1 in prostate cancer have been published. In this review, we focus on the most relevant ETS gene fusions and summarize the current knowledge of the role of ETS transcription factors in prostate cancer. Finally, we discuss the clinical relevance of TMRPSS2–ERG and other ETS gene fusions in prostate cancer.
    [Show full text]
  • ETV6 Gene ETS Variant 6
    ETV6 gene ETS variant 6 Normal Function The ETV6 gene provides instructions for producing a protein that functions as a transcription factor, which means that it attaches (binds) to specific regions of DNA and controls the activity of certain genes. The ETV6 protein is found in the nucleus of cells throughout the body, where it turns off (represses) gene activity. It plays a key role in development before birth and in regulating blood cell formation. Health Conditions Related to Genetic Changes PDGFRB-associated chronic eosinophilic leukemia PDGFRB-associated chronic eosinophilic leukemia, a type of cancer of blood-forming cells, can be caused by a genetic rearrangement known as a translocation that brings together part of the ETV6 gene and part of another gene called PDGFRB, creating the ETV6-PDGFRB fusion gene. The translocation that leads to the ETV6-PDGFRB fusion gene is a somatic mutation, which is acquired during a person's lifetime and occurs initially in a single cell. This cell continues to grow and divide, producing a group of cells with the same mutation (a clonal population). The protein produced from the ETV6-PDGFRB fusion gene, called ETV6/PDGFRb , functions differently than the proteins normally produced from the individual genes. Unlike the normal PDGFRb protein, the fusion protein is always active, which means certain cell signaling pathways are constantly turned on. The fusion protein is unable to repress gene activity regulated by the normal ETV6 protein, so gene activity is increased. The overactive signaling pathways and abnormal gene activity increase the proliferation and survival of cells. When the ETV6-PDGFRB fusion gene mutation occurs in cells that develop into blood cells, the growth of white blood cells called eosinophils (and occasionally other white blood cells, such as neutrophils and mast cells) is poorly controlled, leading to PDGFRB-associated chronic eosinophilic leukemia.
    [Show full text]
  • Data Integration for Identification of Important Transcription Factors of STAT6-Mediated Cell Fate Decisions
    Data integration for identification of important transcription factors of STAT6-mediated cell fate decisions M. Jargosch1*, S. Kröger2*, E. Gralinska1, U. Klotz1,3, Z. Fang1, W. Chen4, U. Leser2, J. Selbig3, D. Groth3 and R. Baumgrass1 1Signal Transduction, German Rheumatism Research Center (DRFZ), Berlin, Germany 2Knowledge Management in Bioinformatics, Humboldt-Universität zu Berlin, Berlin, Germany 3Bioinformatics Group, University of Potsdam, Potsdam, Germany 4Scientific Genomics Platform, Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany *These authors contributed equally to this study. Corresponding author: R. Baumgrass E-mail: [email protected] Genet. Mol. Res. 15 (2): gmr.15028493 Received January 26, 2016 Accepted March 17, 2016 Published June 24, 2016 DOI http://dx.doi.org/10.4238/gmr.15028493 ABSTRACT. Data integration has become a useful strategy for uncovering new insights into complex biological networks. We studied whether this approach can help to delineate the signal transducer and activator of transcription 6 (STAT6)-mediated transcriptional network driving T helper (Th) 2 cell fate decisions. To this end, we performed an integrative analysis of publicly available RNA-seq data of Stat6- knockout mouse studies together with STAT6 ChIP-seq data and our own gene expression time series data during Th2 cell differentiation. We focused on transcription factors (TFs), cytokines, and cytokine receptors and delineated 59 positively and 41 negatively STAT6-regulated genes, Genetics and Molecular Research 15 (2): gmr.15028493 ©FUNPEC-RP www.funpecrp.com.br M. Jargosch et al. 2 which were used to construct a transcriptional network around STAT6. The network illustrates that important and well-known TFs for Th2 cell differentiation are positively regulated by STAT6 and act either as activators for Th2 cells (e.g., Gata3, Atf3, Satb1, Nfil3, Maf, and Pparg) or as suppressors for other Th cell subpopulations such as Th1 (e.g., Ar), Th17 (e.g., Etv6), or iTreg (e.g., Stat3 and Hif1a) cells.
    [Show full text]
  • Deregulation of the HOXA9/MEIS1 Axis in Acute Leukemia
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by IUPUIScholarWorks Author manuscript Author ManuscriptAuthor Manuscript Author Curr Opin Manuscript Author Hematol. Author Manuscript Author manuscript; available in PMC 2017 October 23. Published in final edited form as: Curr Opin Hematol. 2016 July ; 23(4): 354–361. doi:10.1097/MOH.0000000000000245. Deregulation of the HOXA9/MEIS1 Axis in Acute Leukemia Cailin T. Collins1 and Jay L. Hess2 1Department of Pathology, University of Michigan, Ann Arbor, MI 48109 2Indiana University School of Medicine, Indianapolis, IN 46202 Abstract Purpose of review—HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, where its over expression is strongly correlated with poor prognosis. This review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. Recent findings—A variety of genetic alterations including MLL-translocations, NUP98- fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 over expression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21 and mir-196b and many others provide another avenue for potential drug development.
    [Show full text]